Immuno-Oncology | Specialty

Dr. Cheng on Advances With Immunotherapy-Based Combinations in Oncology

November 19th 2021

Jonathan D. Cheng, MD, discusses advances with immunotherapy-based combinations in oncology.

FDA Approves Adjuvant Pembrolizumab for RCC

November 18th 2021

The FDA has approved pembrolizumab for the adjuvant treatment of patients with renal cell carcinoma who are at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.

Innate Cell Engager Demonstrates Evidence of Improved EGFR Inhibition in Tumor Cell Lines

November 12th 2021

The innate cell engager AFM24 showed greater efficacy in eliciting antibody-dependent cellular phagocytosis of EGFR wild-type and KRAS-mutant tumor cells compared with cetuximab.

Immunotherapy Paves Path for New Standards of Care in Gastroesophageal Cancers

November 11th 2021

It is crucial to understand and interpret the results from the landmark clinical trials in the context of recent FDA approvals in gastroesophageal cancers.

Recent Developments Solidify Role of Immunotherapy in Advanced Urothelial Carcinoma

November 11th 2021

Matthew Galsky, MD, discusses the role of immunotherapy in urothelial cancer, as well as unmet needs and future research directions for this patient population.

Nivolumab Plus Low-Dose Ipilimumab Provides Robust, Durable Clinical Benefit in Frontline MSI-H/dMMR mCRC

November 10th 2021

The combination of nivolumab and low-dose ipilimumab resulted in a deep and durable clinical benefit when used in the first-line treatment of patients with microsatellite instability–high and mismatch repair deficient metastatic colorectal cancer.

Immunotherapy/Chemo Combos Remain Go-To Option in Growing Small Cell Lung Cancer Paradigm

November 6th 2021

Chemoimmunotherapy is the new frontline standard of care for patients with small cell lung cancer, and other novel agents, such as, bispecific T-cell engagers are in the pipeline and gaining momentum for those who experience disease progression.

Research With Cellular Therapy Ramps Up in Mesothelioma

November 5th 2021

Marjorie G. Zauderer, MD, previews some of the new approaches in mesothelioma.

Adjuvant Pembrolizumab Maintains RFS Benefit in Resected High-Risk Stage II Melanoma

November 1st 2021

Adjuvant pembrolizumab continued to showcase improved relapse-free survival over placebo in patients with resected high-risk stage II melanoma with 6 months of additional follow-up.

FDA Grants Priority Review to Toripalimab for Nasopharyngeal Carcinoma

November 1st 2021

The FDA has accepted for review a biologics license application for the use of toripalimab in combination with gemcitabine and cisplatin in the frontline treatment of patients with advanced recurrent or metastatic nasopharyngeal carcinoma, and for use as a single agent in the second- or later-line treatment of patients with recurrent or metastatic nasopharyngeal carcinoma following platinum-containing chemotherapy.

Investigators Prepare for the Next Wave of Immunotherapy Advances

October 28th 2021

Since Charu Aggarwal, MD, MPH, helped conduct the first phase 1 trial of pembrolizumab nearly a decade ago, she has been recognized as a pioneer in testing immunotherapy treatments for thoracic cancers.

Nemvaleukin Alfa Plus Pembrolizumab Gets Fast Track Status for Platinum-Resistant Ovarian Cancer

October 26th 2021

The FDA has granted a fast track designation to the interleukin-2 variant immunotherapy nemvaleukin alfa for use in combination with pembrolizumab in the treatment of patients with platinum-resistant ovarian cancer.

Agenus Withdraws BLA for Balstilimab in Metastatic Cervical Cancer

October 22nd 2021

The immuno-oncology company Agenus has made the decision to withdraw its biologic license application for the use of the PD-1 inhibitor balstilimab in patients with recurrent or metastatic cervical cancer who experienced disease progression on, or after, chemotherapy.

Pembrolizumab/Chemo Approved in Europe for Select Locally Recurrent Unresectable or Metastatic TNBC

October 22nd 2021

The European Commission has approved pembrolizumab plus chemotherapy for the frontline treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors have a PD-L1 expression combined positive score of 10 or higher and who have not previously received chemotherapy for metastatic disease.

FDA Approves Companion Diagnostic for Adjuvant Atezolizumab in Stage II to IIIA NSCLC

October 22nd 2021

The FDA has approved the VENTANA PD-L1 assay to assist in identifying which adult patients with stage II to IIIA non–small cell lung cancer whose tumors have PD-L1 expression on 1% or more of tumor cells are eligible to receive adjuvant atezolizumab following surgery and platinum-based chemotherapy.

Nivolumab/Chemo Approved in Europe for HER2– Advanced or Metastatic Gastric, GEJ, or Esophageal Adenocarcinoma

October 21st 2021

The European Commission has approved nivolumab plus fluoropyrimidine- and platinum-based chemotherapy for the frontline treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma whose tumors have a PD-L1 combined positive score of 5 or higher.

Chemoimmunotherapy Combos, Adjuvant Approaches and Bispecifics Are Among Exciting Advances in Lung Cancer

October 19th 2021

The availability of chemoimmunotherapy combinations and targeted agents for common and rare mutations alike in non–small cell lung cancer has fostered discussions that might have been unthinkable just a decade or so ago.

Dr. Johnson on the Promise of DS-7300 in SCLC and Other Advanced Solid Tumors

October 13th 2021

Melissa L. Johnson, MD, discusses the promise of DS-7300 in small cell lung cancer and other advanced solid tumors.

IO Combo Anchors a New Front Line Taking Shape in Unresectable HCC

October 13th 2021

The tide is starting to turn toward more effective frontline systemic therapies for patients with unresectable hepatocellular carcinoma as a result of the introduction of a novel immune-oncology combination.

Nivolumab/Cabozantinib Continues to Showcase Deep, Durable Responses in Advanced RCC

October 11th 2021

Nivolumab plus cabozantinib continued to significantly improve overall response rate vs sunitinib in patients with previously untreated, advanced renal cell carcinoma, with meaningful response outcomes observed irrespective of dose modifications with cabozantinib and fewer responders in the doublet arm requiring subsequent treatment.